Team:Stanford-Brown/HumanPractices/PatentEthics

From 2012.igem.org

(Difference between revisions)
(Patent Ethics)
Line 15: Line 15:
== '''Patent Ethics''' ==
== '''Patent Ethics''' ==
-
Coming soon!
+
In addition to the Synbio Community’s practical need for a guide to help navigate patent law, we also felt it would be invaluable to invigorate the discussion surrounding the ethics of gene patents. Thus we crafted a gene patent ethics review to complement our more practical guide. This review includes two documents, a full paper on the topic as well as an “at a glance” document for those who want to start thinking about these issues in a less rigorous fashion.
 +
 
 +
As an introduction, it has been estimated that approximately 20% of the human genome is patented . While this is a generalized statement, most would find this notion, at least in part, unsettling. As synthetic biology is a relatively new field with unprecedented possibilities, indubitably, there is a great debate surrounding gene patenting in moral, practical, and legal domains.
 +
 
 +
The two documents below seek to elucidate the variety of dilemmas that the synbio-patent interaction has provoked and to hopefully offer some objective commentary and insight for the iGEM and greater synthetic biology community.

Revision as of 17:59, 3 October 2012


Patent Ethics

In addition to the Synbio Community’s practical need for a guide to help navigate patent law, we also felt it would be invaluable to invigorate the discussion surrounding the ethics of gene patents. Thus we crafted a gene patent ethics review to complement our more practical guide. This review includes two documents, a full paper on the topic as well as an “at a glance” document for those who want to start thinking about these issues in a less rigorous fashion.

As an introduction, it has been estimated that approximately 20% of the human genome is patented . While this is a generalized statement, most would find this notion, at least in part, unsettling. As synthetic biology is a relatively new field with unprecedented possibilities, indubitably, there is a great debate surrounding gene patenting in moral, practical, and legal domains.

The two documents below seek to elucidate the variety of dilemmas that the synbio-patent interaction has provoked and to hopefully offer some objective commentary and insight for the iGEM and greater synthetic biology community.